Plant Name: Sophora tomentosa
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.280E-12 | 2.786E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.214E-11 | 4.588E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 7.325E-10 | 3.987E-06 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 3.565E-09 | 1.553E-05 | AKR1B1, CYP1A2, CYP2C19, CYP2C9, CYP3A4, ESR1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.255E-08 | 4.554E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.193E-08 | 5.969E-05 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 4.017E-08 | 9.720E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.421E-07 | 5.220E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 3.538E-07 | 6.420E-04 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 5.492E-07 | 7.973E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.739E-07 | 1.119E-03 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.084E-06 | 1.312E-03 | CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 2.121E-06 | 2.023E-03 | ESR1, ESR2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.131E-06 | 2.023E-03 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 7.417E-06 | 5.569E-03 | CYP1A2, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.750E-09 | 2.240E-07 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 7.476E-08 | 3.190E-06 | MAPK1; ESR1; NFKB1; ESR2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.289E-08 | 3.190E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.267E-07 | 4.054E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 7.059E-06 | 1.807E-04 | CYP2C9; CYP1A2; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.002E-05 | 2.138E-04 | CYP2C9; CYP1A2; CYP3A4 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.506E-05 | 4.582E-04 | MAPK1; ESR1; ESR2 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.731E-05 | 5.307E-04 | CYP2C9; CYP1A2; AKR1B1; CYP2C19; CYP3A4; HSD17B10 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.625E-05 | 5.307E-04 | CYP2C9; MAPK1; CYP2C19 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 7.052E-05 | 9.026E-04 | LMNA; MAPK1; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 5.171E-04 | 5.272E-03 | MAPK1; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 6.117E-04 | 5.544E-03 | CYP2C9; CYP2C19 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 6.929E-04 | 5.544E-03 | MAPK1; NFKB1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 5.171E-04 | 5.272E-03 | MAPK1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 8.470E-04 | 5.706E-03 | MAPK1; NFKB1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 5.354E-04 | 5.272E-03 | CYP1A2; CYP3A4 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 8.470E-04 | 5.706E-03 | MAPK1; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.612E-03 | 8.410E-03 | MAPK1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 8.470E-04 | 5.706E-03 | MAPK1; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 6.722E-04 | 5.544E-03 | MAPK1; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.255E-03 | 7.304E-03 | MAPK1; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 8.938E-04 | 5.720E-03 | MAPK1; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.676E-03 | 8.410E-03 | MAPK1; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.173E-03 | 7.149E-03 | MAPK1; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.708E-03 | 8.410E-03 | MAPK1; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.774E-03 | 8.410E-03 | MAPK1; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.708E-03 | 8.410E-03 | MAPK1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.908E-03 | 8.725E-03 | MAPK1; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 2.192E-03 | 9.062E-03 | MAPK1; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.192E-03 | 9.062E-03 | MAPK1; ESR1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 2.265E-03 | 9.062E-03 | MAPK1; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.732E-03 | 1.044E-02 | MAPK1; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.265E-03 | 9.062E-03 | MAPK1; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.330E-03 | 1.184E-02 | MAPK1; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.773E-03 | 1.044E-02 | MAPK1; NFKB1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 4.743E-03 | 1.598E-02 | MAPK1; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 4.380E-03 | 1.515E-02 | MAPK1; HSD17B10 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 6.328E-03 | 1.920E-02 | MAPK1; ESR1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 5.396E-03 | 1.727E-02 | MAPK1; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 4.903E-03 | 1.609E-02 | MAPK1; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 6.089E-03 | 1.901E-02 | MAPK1; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 6.449E-03 | 1.920E-02 | MAPK1; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 7.854E-03 | 2.285E-02 | MAPK1; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 9.824E-03 | 2.794E-02 | MAPK1; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.315E-02 | 3.659E-02 | MAPK1; NFKB1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.709E-02 | 4.510E-02 | MAPK1; NFKB1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.727E-02 | 4.510E-02 | MAPK1 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 1.608E-02 | 4.380E-02 | MAPK1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.786E-02 | 4.571E-02 | AKR1B1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.904E-02 | 4.778E-02 | AKR1B1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.997E-03 | 1.096E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; NFKB1; ESR1; ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; ESR1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |